Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Income from Continuing Operations (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Income from Continuing Operations for 16 consecutive years, with 31715000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 254.57% year-over-year to 31715000.0; the TTM value through Mar 2026 reached 47365000.0, down 64.66%, while the annual FY2025 figure was 99652000.0, 29.43% down from the prior year.
  • Income from Continuing Operations hit 31715000.0 in Q1 2026 for Corcept Therapeutics, down from 24288000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 47243000.0 in Q3 2024 and bottomed at 31715000.0 in Q1 2026.
  • Average Income from Continuing Operations over 5 years is 24513352.94, with a median of 27528000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations surged 88.85% in 2023 and then tumbled 254.57% in 2026.
  • Corcept Therapeutics' Income from Continuing Operations stood at 16603000.0 in 2022, then soared by 88.85% to 31355000.0 in 2023, then fell by 1.85% to 30776000.0 in 2024, then dropped by 21.08% to 24288000.0 in 2025, then tumbled by 230.58% to 31715000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 31715000.0, 24288000.0, and 19643000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.